LB Pharmaceuticals Inc Common Stock
LBRXHealthcare|Biotechnology|US
$42.01
+3.92 (+10.29%)
DCF Value
$9.67
Tangible Book / Share
$12.63
Cash / Share
$12.21
About
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Stock Price
+170.9%(1Y)
1M
+21.4%
3M
-12.5%
6M
+31.4%
YTD
+88.7%
1Y
+187.5%
3Y
+142.8%
5Y
+142.8%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$1.36B
Employees27
CEOHeather D. Turner
IPO DateSep 11, 2025
Beta0.42
52-Week Range$14.317 – $50.16
Avg Volume358,103
ExchangeNASDAQ
Websitelbpharma.us
Ownership
Float82.3%
Shares Outstanding32.3M
Recent Insider Trades
Miller Joseph MAWARD
Oct 9, 2026200,000 shares @ $37.22
Kozauer Susan GaniAWARD
Oct 9, 2026200,000 shares @ $37.22
Kozauer Susan GaniOTHER
Sep 14, 20260 shares
Miller Joseph MOTHER
Sep 2, 20260 shares
Deep Track Biotechnology Master Fund, Ltd.BUY
Jul 30, 2026286,205 shares @ $0.00
Peers
Recent News
Biotech Is Booming; Here Are 4 Names Outperforming Despite This Deep Correction
Nov 8, 2026 · seekingalpha.com
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 5, 2026 · globenewswire.com
LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
Oct 27, 2026 · marketbeat.com
LB Pharmaceuticals to Participate in Upcoming Investor Events
Oct 15, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:19 AM